Zoetis Inc. $ZTS Shares Bought by Benin Management CORP

Benin Management CORP grew its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 2.0% in the second quarter, HoldingsChannel reports. The fund owned 4,901 shares of the company’s stock after buying an additional 95 shares during the period. Benin Management CORP’s holdings in Zoetis were worth $764,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently added to or reduced their stakes in ZTS. Nova Wealth Management Inc. acquired a new position in Zoetis during the 1st quarter worth $25,000. 1248 Management LLC bought a new stake in shares of Zoetis in the 1st quarter worth $27,000. Saudi Central Bank bought a new stake in shares of Zoetis in the 1st quarter worth $29,000. Cornerstone Planning Group LLC raised its stake in shares of Zoetis by 79.3% in the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock worth $30,000 after buying an additional 88 shares in the last quarter. Finally, REAP Financial Group LLC raised its stake in shares of Zoetis by 201.5% in the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after buying an additional 131 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Up 0.7%

NYSE:ZTS opened at $146.13 on Wednesday. The firm has a market capitalization of $64.76 billion, a price-to-earnings ratio of 25.15, a PEG ratio of 2.33 and a beta of 0.90. Zoetis Inc. has a 1-year low of $139.34 and a 1-year high of $189.98. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The business’s fifty day moving average price is $148.58 and its 200 day moving average price is $153.55.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. During the same period in the previous year, the firm earned $1.56 earnings per share. Zoetis’s quarterly revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, sell-side analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be paid a $0.50 dividend. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 annualized dividend and a dividend yield of 1.4%. Zoetis’s dividend payout ratio (DPR) is currently 34.42%.

Analyst Ratings Changes

A number of research firms have recently commented on ZTS. Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a research note on Wednesday, October 8th. Piper Sandler boosted their price objective on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Leerink Partners downgraded Zoetis from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. UBS Group cut their target price on Zoetis from $165.00 to $158.00 and set a “neutral” rating on the stock in a research report on Monday. Finally, Argus reaffirmed a “buy” rating and set a $190.00 target price on shares of Zoetis in a research report on Tuesday, September 9th. Four research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $195.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.